FATE
FATE
NASDAQ · Biotechnology

Fate Therapeutics Inc

$2.70
+0.28 (+11.57%)
As of Jun 30, 10:31 PM ET ·
Analyst Consensus
Buy
18
Analysts
High
Coverage
Buy 11 61%
Hold 7 39%
Sell 0 0%
Price Target
Analyst Price Target +113.0% upside
Low Target $4.43
Average Target $5.75
High Target $6.69
Current Price $2.70
Current
$2.70
Target
$5.75
$4.43 $5.75 avg $6.69
Scenario Analysis
Bear Case
$4.43
64.1%
Low target
Base Case
$5.75
+113.0%
Avg target
Bull Case
$6.69
+147.8%
High target
Risk/Reward
2.3x
Favorable
Price in Context
52-Week High
$2.88
-6.2% from high
52-Week Low
$0.91
+196.7% from low
Target vs 52W High
$5.75
+99.7% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 40 78% $257.58 +2.4%
AMGN
Amgen Inc
Hold 44 50% $190.87 -47.3%
GILD
Gilead Sciences Inc
Strong Buy 39 82% $362.68 +187.1%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 40 83% $438.34 -11.8%
REGN
Regeneron Pharmaceuticals
Buy 38 71% $76.80 -87.7%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 37 76% $102.31 -66.0%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -39.1%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -47.4%